The New Feinberg Larry N Holding in Biolase, Inc
Feinberg Larry N filed with the SEC SC 13D/A form for Biolase, Inc. The form can be accessed here: 000089914016001637. As reported in Feinberg Larry N’s form, the filler as of late owns 22.04% or 15,079,422 shares of the Health Care–company.
Biolase, Inc stake is a new one for the and it was filed because of activity on September 30, 2016. We feel this shows Feinberg Larry N’s positive view for the stock.
Reasons Why Feinberg Larry N Bought – Biolase, Inc Stock
Item 4. Purpose of Transaction
Item 4 of the Statement is hereby supplemented as follows:
On September 30, 2016, the Issuer held a special meeting of its stockholders (the “
”) at which the stockholders were asked to vote, among other things, to ratify the terms and issuance of the Preferred Stock (defined in Amendment No. 12) and related Warrants, including the removal of the 19.99% Limitation, and to approve the issuance of such number of Shares issuable upon full conversion of the Preferred Stock and upon the full exercise of the Warrants, in each case, including shares issuable pursuant to customary anti-dilution provisions (the “
”). The stockholders voted to approve the Issuance Proposal at the Special Meeting, upon which each share of Preferred Stock automatically converted into 100 Shares, for an aggregate of 3,699,100 shares issued to the Reporting Person and reflecting a conversion price of $1.13 per Share (the “
”), and the 19.99% Limitation was removed from the Warrants.
Biolase, Inc Institutional Sentiment
Latest Security and Exchange filings show 40 investors own Biolase, Inc. The institutional ownership in Q3 2015 is low, at 55.21% of the outstanding shares. This is increased by 4817022 the total institutional shares. 32421044 were the shares owned by these institutional investors. In total 3 funds opened new Biolase, Inc stakes, 9 increased stakes. There were 4 that closed positions and 9 reduced them.
Princeton Capital Management Inc is an institutional investor bullish on Biolase, Inc, owning 443701 shares as of Q3 2015 for 0.24% of its portfolio. Stephen Dubois Camber Capital Management Llc owns 5332394 shares or 0.41% of its portfolio. CT Oracle Investment Management Inc have 1.93% of their stock portfolio for 10474725 shares. Further, Consonance Capital Management Lp reported stake worth 0.15% of its US stock portfolio. The VT Birchview Capital Lp owns 1185903 shares. Biolase, Inc is 1.09% of the manager’s US portfolio.
BIOLASE, Inc. (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers. It offers two categories of laser system products: WaterLase (all-tissue) systems and Diode (soft tissue) systems. Its brand, WaterLase, uses a combination of water and laser energy to perform procedures performed using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. It also offers its Diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. Its Waterlase and Diode systems use disposable laser tips of differing sizes and shapes depending on the procedures being performed.
SEC Form 13D is filed within 10 days, by anyone who acquires beneficial ownership of 5%+ of any public firm. Activist investors and practices such as: company breakups, hostile takeovers, and change of control events, are permitted for this form filers. A filer must promptly update its 13D filing in case of acquisition or disposition of 1% or more of the securities that are the subject of the filing.
Insitutional Activity: The institutional sentiment decreased to 1 in Q2 2016. Its down 0.25, from 1.25 in 2016Q1. The ratio is negative, as 6 funds sold all BIOLASE Inc shares owned while 7 reduced positions. 4 funds bought stakes while 9 increased positions. They now own 23.37 million shares or 0.00% more from 23.37 million shares in 2016Q1.
Teton Advsr reported 341,461 shares or 0.04% of all its holdings. The New York-based Consonance Cap Management L P has invested 0.21% in BIOLASE Inc (NASDAQ:BIOL). Jnba Financial Advsr last reported 1,096 shares in the company. The Germany-based Deutsche Bank & Trust Ag has invested 0% in BIOLASE Inc (NASDAQ:BIOL). Guggenheim Cap Ltd Liability Corp accumulated 0% or 12,700 shares. Bancorp Of New York Mellon Corporation holds 0% of its portfolio in BIOLASE Inc (NASDAQ:BIOL) for 42,222 shares. Blackrock Fund Advsrs last reported 0% of its portfolio in the stock. Gabelli Funds Lc holds 0% or 43,000 shares in its portfolio. Barnett & Co has 439 shares for 0% of their US portfolio. Northern Tru Corporation reported 89,335 shares or 0% of all its holdings. Bank Of America De, a North Carolina-based fund reported 2,836 shares. Manufacturers Life Communication The accumulated 0% or 1,562 shares. Moreover, Blackrock Advsrs Limited Company has 0% invested in BIOLASE Inc (NASDAQ:BIOL) for 11,125 shares. The California-based Wells Fargo And Mn has invested 0% in BIOLASE Inc (NASDAQ:BIOL). Gamco Invsts Inc Et Al holds 0% of its portfolio in BIOLASE Inc (NASDAQ:BIOL) for 91,455 shares.
Analysts await BIOLASE Inc (NASDAQ:BIOL) to report earnings on November, 2.
The stock closed at $1.6 during the last session. It is down 68.42% since March 3, 2016 and is uptrending. It has outperformed by 60.08% the S&P500.
BIOLASE, Inc. is a medical device firm that develops, makes, markets and sells laser systems in dentistry and medicine. The company has a market cap of $96.36 million. The Firm markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers. It currently has negative earnings. It offers two categories of laser system products: WaterLase (all-tissue) systems and Diode (soft tissue) systems.
Another recent and important BIOLASE Inc (NASDAQ:BIOL) news was published by Thestreet.com which published an article titled: “Why Biolase (BIOL) Stock Is Higher Today” on June 17, 2014.
According to Zacks Investment Research, “Biolaw Technology, Inc. is the world’s leading dental laser company, is a medical technology company that develops, manufactures and markets lasers and related products focused on technologies that advance the practice of dentistry and medicine. The Company’s products incorporate patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. BIOLASE’s principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. Other products under development address ophthalmology and other medical and consumer markets.”
BIOL Company Profile
BIOLASE, Inc. (BIOLASE), incorporated on February 10, 1987, is a medical device firm that develops, makes, markets and sells laser systems in dentistry and medicine. The Firm markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers. The Company’s dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative and complex surgical applications. Combining its laser system products with imaging solutions provides dental professionals capabilities for early diagnosis and minimally invasive treatment. It markets and sells its laser systems in Canada, the European Union and other countries outside the United States.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.